Greater incentive for original drug discovery will create opportunities for Indian companies to develop new competencies through collaborative research and global alliances

Big pharma and biotech companies to choose India as the preferred hub for their global R&D and manufacturing operations

Increasing cost of drug discovery & development and the increasing time to market

Declining R&D productivity (high attrition rates and cost of failures

Increasing regulatory demands of the USFDA for drug

Complexion of the Health Science industry to alter significantly post 2005

Global competitiveness will be the key to growth and survival under the new IPR regime

The increase in the population share of the elderly is also causing a change in the pattern of demand for healthcare services. Such change is opening up both preventive and curative care opportunities, which the existing and new players are exploiting. For instance, in-patient capacity in cardiac care is close to the point of reaching excess supply in certain cities.

Hospitals would organize their resources and manpower within structures that had evolved rather than been designed. The processes would be structured to ensure multiple points of control rather than patient convenience. Information capture would be rudimentary and information rarely integrated beyond that required for reporting purposes, because of which any data-based quality control would not be possible.